Company Overview
Company Name
Alumis
Address
280 E Grand Ave., South San Francisco, CA, 94080, United States
Website
alumis.comPhone
(650) 231-6625Approx. Annual Revenue
$22.0M
Employees
120
Established
2003
About Alumis
Alumis Inc., a biopharmaceutical company based in South San Francisco, CA, is focused on developing precision therapies to transform the lives of patients with immune-mediated diseases. With approximately 24 employees, the company is pioneering a targeted approach to address the underlying drivers of immune dysfunction and deliver optimal clinical outcomes for patients.
Business Profile
Read from the Alumis website on Oct 27, 2026. Hover an item to see the exact wording it came from.
About the website
- Website quality (AI-assessed)
- 8/10 · Current news and pipeline updates; Clear navigation and contact information
- Footer copyright year
- 2026
Recent changes
What changed on the Alumis website and Google listing, as detected by Coldlytics on each visit.
Estimated revenue band moved from $500K-1M to $10M-25M
Estimated headcount moved from 2-5 to 101-250 employees
Coldlytics tracks changes like these across millions of businesses, so you can reach companies the moment they add a pixel, start hiring, or switch software.
Find companies by what just changed →Biotech & Life Sciences Companies near South San Francisco, CA
- Unity Biotechnologyunitybiotechnology.com
- Insitroinsitro.com
- ALX Oncologyalxoncology.com
- ORIC Pharmaceuticalsoricpharma.com
- Allogene Therapeuticsallogene.com
- Mission Biomissionbio.com
- Structure Therapeuticsstructuretx.com
- Denali Therapeuticsdenalitherapeutics.com
- Alectoralector.com
- CytomX Therapeuticscytomx.com
Frequently Asked Questions about Alumis
Categories
Technologies Used
%20--%3e%3csvg%20version='1.1'%20id='st_x5F_cc_x5F_app_x5F_RGB.svg'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20240.0004%20234.0004'%20style='enable-background:new%200%200%20240.0004%20234.0004;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:url(%23SVGID_1_);}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3clinearGradient%20id='SVGID_1_'%20gradientUnits='userSpaceOnUse'%20x1='119.9997'%20y1='234.0002'%20x2='119.9997'%20y2='0.0002'%3e%3cstop%20offset='0'%20style='stop-color:%23201F21'/%3e%3cstop%20offset='1'%20style='stop-color:%23313131'/%3e%3c/linearGradient%3e%3crect%20x='-0.0003'%20y='0.0002'%20class='st0'%20width='240'%20height='234'/%3e%3cg%3e%3cpath%20class='st1'%20d='M132.24969,97.95853c-5.60328,18.77988-10.28088,36.91208-15.88416,54.63138%20c-3.18081,9.99579-6.66385,19.53729-11.05544,25.59485c-4.84678,6.81497-13.93402,13.32771-24.83743,13.32771%20c-7.72443,0-15.29683-3.63509-15.29683-11.66174c0-4.99789,5.14901-9.69264,9.23837-9.69264%20c2.42339,0,3.63508,1.36282,4.24046,2.42339c3.7862,6.81497,7.42128,10.75229,9.08724,10.75229s3.02878-2.27135,5.7544-12.1151%20l19.82331-73.26013H99.08337c-1.06058-3.18081,0.45427-7.11812,2.27135-7.87554h14.23625%20c2.72562-8.7841,5.92356-17.60862,10.46719-25.63529c6.81497-12.26713,17.7193-21.95976,32.71205-21.95976%20c11.3586,0,16.05333,5.45216,16.05333,12.41917c-0.15111,7.42036-6.66293,11.20656-9.69263,11.20656%20c-2.42247,0-3.63416-1.81709-4.39159-4.39159c-2.57451-9.69263-5.90643-12.57029-7.87555-12.57029%20c-1.9682,0-4.99789,3.63416-8.3289,11.20656c-4.3925,9.54151-7.28729,19.72977-10.01291,29.72464h17.26501%20c1.05966,2.12023,0.15112,6.66385-2.42339,7.87554H132.24969z'/%3e%3c/g%3e%3c/svg%3e)
Social Profiles
Key Decision Makers
Elisa Muscianisi Vice President Clinical Development
Ryan Togashi Sr. Clinical Trial Manager / Clinical Trial Manager
Erica C. Clinical Trial Manager
Catherine Nguyen Clinical Trial Manager
Amanda Yang Clinical Trial Manager
Rachel Day Clinical Trials Manager
Michiel Kesarsing Clinical Trial Manager